|
Design Therapeutics, Inc. (DSGN) DCF Valoración
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Design Therapeutics, Inc. (DSGN) Bundle
¡Mejore sus opciones de inversión con la calculadora DCF de diseño Therapeutics, Inc. (DSGN)! Sumérgete en datos financieros reales, ajusta las proyecciones y gastos de crecimiento, y observa instantáneamente cómo estas modificaciones afectan el valor intrínseco de Design Therapeutics, Inc. (DSGN).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | -72.9 | -100 | 0 | 0 | -43.23 | -43.23 | -43.23 | -43.23 | -43.23 |
| EBITDA | -.1 | -8.3 | -35.7 | -62.8 | -66.3 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | -16666.67 | -3683628.32 | 100 | 100 | 100 | 20 | 20 | 20 | 20 | 20 |
| Depreciation | 1.9 | .0 | .1 | .5 | .5 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 228776.98 | 2212.39 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -2.0 | -8.3 | -35.8 | -63.3 | -66.9 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | -245443.65 | -3685840.71 | 100 | 100 | 100 | 20 | 20 | 20 | 20 | 20 |
| Total Cash | .1 | 36.1 | 384.1 | 330.4 | 281.8 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | 16.0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .1 | 1.1 | 1.4 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 0 | 4424.78 | 100 | 100 | 100 | 80 | 80 | 80 | 80 | 80 |
| Inventories | .0 | .1 | 1.3 | -1.1 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 47345.13 | 100 | 100 | 100 | 80 | 80 | 80 | 80 | 80 |
| Accounts Payable | 2.5 | 1.4 | 1.6 | 3.0 | 1.9 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 297242.21 | 619026.55 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | -.1 | -1.5 | -.9 | -.3 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 0 | -33628.32 | 100 | 100 | 100 | -20 | -20 | -20 | -20 | -20 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -2.0 | -8.3 | -35.8 | -58.6 | -66.9 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 2.3 | -9.6 | -38.3 | -56.3 | -69.1 | -.5 | .0 | .0 | .0 | .0 |
| WACC, % | 13.03 | 13.03 | 13.03 | 13.02 | 13.03 | 13.03 | 13.03 | 13.03 | 13.03 | 13.03 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | 0 | |||||||||
| Net Debt | -18 | |||||||||
| Equity Value | 18 | |||||||||
| Diluted Shares Outstanding, MM | 56 | |||||||||
| Equity Value Per Share | 0.32 |
What You Will Receive
- Authentic DSGN Financial Data: Pre-loaded with Design Therapeutics’ historical and projected figures for accurate analysis.
- Completely Customizable Template: Easily adjust key inputs such as revenue growth, WACC, and EBITDA %.
- Instant Calculations: Watch as Design Therapeutics’ intrinsic value updates in real-time with your modifications.
- Expert Valuation Tool: Tailored for investors, analysts, and consultants aiming for precise DCF outcomes.
- Intuitive Design: Clear layout and straightforward instructions suitable for all skill levels.
Key Features
- Comprehensive DCF Model: Features both unlevered and levered DCF valuation frameworks tailored for Design Therapeutics, Inc. (DSGN).
- WACC Tool: A pre-configured Weighted Average Cost of Capital calculator with adjustable parameters.
- Customizable Forecast Inputs: Adjust growth projections, capital investments, and discount rates as needed.
- Integrated Financial Ratios: Evaluate profitability, leverage, and operational efficiency ratios specific to Design Therapeutics, Inc. (DSGN).
- Interactive Dashboard and Visuals: Graphical representations that encapsulate essential valuation indicators for straightforward analysis.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Design Therapeutics, Inc.'s (DSGN) pre-filled financial data and forecasts.
- Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you adjust assumptions.
- Step 5: Analyze the outputs and leverage the results for investment decisions.
Why Choose This Calculator for Design Therapeutics, Inc. (DSGN)?
- Accuracy: Leverages real Design Therapeutics financials for precise data.
- Flexibility: Built to allow users to easily test and adjust inputs.
- Time-Saving: Eliminate the need to create a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and usability expected at the CFO level.
- User-Friendly: Intuitive design makes it accessible for users without extensive financial modeling skills.
Who Should Use This Product?
- Investors: Evaluate Design Therapeutics, Inc.'s (DSGN) potential for investment by estimating its fair value.
- CFOs: Utilize a sophisticated DCF model for accurate financial reporting and analysis related to Design Therapeutics, Inc. (DSGN).
- Consultants: Easily customize the template for valuation reports tailored to clients interested in Design Therapeutics, Inc. (DSGN).
- Entrepreneurs: Discover financial modeling techniques employed by leading biotech firms, including Design Therapeutics, Inc. (DSGN).
- Educators: Implement it as a resource for teaching valuation methodologies relevant to the biotech industry, like that of Design Therapeutics, Inc. (DSGN).
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Design Therapeutics, Inc. (DSGN) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Design Therapeutics, Inc. (DSGN).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.